Novartis

Pharma's giants, new and old, tell more tales than their numbers show
Pharma's giants, new and old, tell more tales than their numbers show
Fierce Pharma
Big Pharma
JNJ
Pfizer
GSK
Roche
Novartis
Sanofi
Bristol-Myers Squibb
Flag link:
New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet
New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet
Fierce Pharma
Novartis
Kisqali
Pfizer
Ibrance
breast cancer
Flag link:
Gilead Could Be Making An Acquisition — But It's Not What You Think
Gilead Could Be Making An Acquisition — But It's Not What You Think
Investors Business Daily
Gilead Sciences
M&A
United Therapeutics
GSK
Novartis
Flag link:
Top Novartis manufacturing exec jumps ship, takes charge of industrializing Moderna’s mRNA tech
Top Novartis manufacturing exec jumps ship, takes charge of industrializing Moderna’s mRNA tech
Endpoints
Novartis
drug manufacturing
Moderna Therapeutics
MRNA
Flag link:
Kite shoots for first CAR-T OK in Europe, staying one step behind Novartis in US race
Kite shoots for first CAR-T OK in Europe, staying one step behind Novartis in US race
Endpoints
Kite Pharma
CAR-T
Europe
Novartis
axicabtagene ciloleucel
Flag link:
Amgen And Novartis: First Mover Advantage Is A Must
Amgen And Novartis: First Mover Advantage Is A Must
Seeking Alpha
Amgen
Novartis
migraines
erenumab
CGRP blockers
Flag link:
EMA Backs Eight New Medicines, Turns Down Drugs From Nektar & Vanda
EMA Backs Eight New Medicines, Turns Down Drugs From Nektar & Vanda
RAPS.org
EMA
Europe
Pfizer
Bavencio
Novartis
Rydapt
Lexicon Pharmaceuticals
Xermelo
Vanda
Fanaptum
Nektar
Onzeald
Daiichi Sankyo
Flag link:
Drugmakers face challenges marketing new heart drugs
Drugmakers face challenges marketing new heart drugs
Medical Marketing and Media
drug marketing
Amgen
Repatha
Novartis
Entresto
Ilaris
canakinumab
Merck
Anacetrapib
Flag link:
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Flag link:
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Endpoints
Amgen
Novartis
migraines
CGRPs
Aimovig
Flag link:
With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round
With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round
Endpoints
Novartis
Sanofi
NeuroVia
X-ALD
Flag link:
Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now
Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now
Endpoints
Novartis
M&A
Pharma CEOs
Joe Jimenez
Flag link:
CAR-T Cell Therapy Is Here To Stay
CAR-T Cell Therapy Is Here To Stay
Forbes
CAR-T
cell therapy
Novartis
Flag link:
Novartis sales down -2% but ahead of estimates in Q2
Novartis sales down -2% but ahead of estimates in Q2
Drug Delivery Business News
Novartis
earnings
Flag link:
Novartis unit Alcon posts modest Q2 gain
Novartis unit Alcon posts modest Q2 gain
Mass Device
Novartis
Alcon
eye health
earnings
devices
Flag link:
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Motley Fool
Novartis
Pfizer
Flag link:
How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals
How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals
Investors Business Daily
Novartis
CAR-T
CTL019
Kite Pharma
Bluebird Bio
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
Novartis wins unanimous support from FDA panel on groundbreaking CAR-T med
Novartis wins unanimous support from FDA panel on groundbreaking CAR-T med
Fierce Pharma
Novartis
CAR-T
FDA
advisory panels
CTL019
Flag link:
D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T
D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T
Endpoints
Novartis
FDA
CAR-T
CTL019
Flag link:

Pages